Zelda Therapeutics Ltd (ASX:ZLD) will use the $769,000 cash refund it received under the Federal Government’s R&D Tax Incentive Scheme to accelerate current clinical trials as well as a pre-clinical program.
The R&D Tax Incentive Scheme is an Australian Government program where companies receive cash refunds of 43.5% if eligible expenditure is on research and development.
The refund positions Zelda well as it advances its current:
- Human clinical trial program – focused on insomnia, autism and opioid reduction with activities in Australia and the USA; and
- Pre-clinical research program – examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.
The company conducts this work in partnership with world-leading researchers and organisations such as Complutense University in Spain, Curtin University in Western Australia, the Telethon Kids Institute in Perth, the University of Western Australia and the Children’s Hospital of Philadelphia in the United States.
In March 2019 Zelda was awarded a patent to detect breast cancer, which details a method for detecting levels of expression of a novel receptor complex containing HER2 and CB2 (types of protein).
HER2 is a well-recognised marker of aggressive breast cancer while CB2 is a key receptor in the endocannabinoid system.